A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Liver Cancer

Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Feb 8, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring how levels of certain substances in the blood and urine change in patients with liver diseases as they develop into liver cancer. Researchers believe that understanding these changes can help with the early detection and treatment of liver cancer, especially in patients who already have conditions like hepatitis, fatty liver, or liver cirrhosis. The study is currently looking for participants who are between the ages of 18 and 75 and have been diagnosed with one of these liver conditions.

To qualify for the study, participants need to meet specific criteria related to their liver health, such as having hepatitis B or fatty liver disease confirmed by medical tests. However, individuals with other serious health issues or a history of certain cancers are not eligible. If you choose to participate, you will undergo tests that measure changes in your blood and urine, which could provide valuable information for better understanding liver cancer and improving future treatments. This trial is important because it aims to uncover clues that could lead to earlier diagnosis and potentially better outcomes for patients with liver cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with hepatitis B: patients who meet the WS299-2008 Diagnostic Standards for Hepatitis B issued by the Ministry of Health.
• • 2. Patients with fatty liver: patients whose liver imaging findings meet the imaging diagnostic criteria for diffuse fatty liver disease or whose liver biopsy histology changes meet the pathological diagnostic criteria for fatty liver disease.
• • 3. Patients with liver cirrhosis: patients who meet the diagnostic criteria of the Guidelines for the Diagnosis and Treatment of Liver Cirrhosis (2019) issued by the Hepatology Branch of the Chinese Medical Association;
• • 4. Liver cancer patients: patients who comply with the Diagnostic and Treatment Standards for Primary Liver Cancer (2019 Edition) issued by the National Health Commission of the People's Republic of China.
• Exclusion Criteria:
• • - 1. People who have a history of non research related liver diseases or other diseases known to affect blood metabolism (except for controlled type II diabetes); 2. Have a history of other malignant tumors, except for fully treated basal cell carcinoma or squamous cell carcinoma and cervical carcinoma in situ; 3. Diseases requiring long-term use of immunosuppressive drugs (including steroids), including but not limited to congenital or acquired immunodeficiency diseases or active central nervous system metastatic cancer, active infection or uncontrolled heart disease; 4. Suffer from other uncontrolled serious diseases at the same time, such as unstable heart disease requiring treatment, diabetes with unsatisfactory control (fasting blood glucose\>1.5 × Upper limit of normal value), mental illness and severe allergic history.
• • 5. BMI is less than 18 or more than 25.